Sandy Spring Bank’s Seres Therapeutics MCRB Stock Holding History

Sandy Spring Bank’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$242	Hold	17	–	–	﹤0.01%	1154
2024 Q4	$287	Hold	17	–	–	﹤0.01%	1154
2024 Q3	$327	Hold	17	–	–	﹤0.01%	1137
2024 Q2	$250	Hold	17	–	–	﹤0.01%	1212
2024 Q1	$268	Hold	17	–	–	﹤0.01%	1177
2023 Q4	$483	Hold	17	–	–	﹤0.01%	1113
2023 Q3	$822	Hold	17	–	–	﹤0.01%	1099
2023 Q2	$1.65K	Hold	17	–	–	﹤0.01%	1082
2023 Q1	$1.96K	Hold	17	–	–	﹤0.01%	1024
2022 Q4	$1.93K	Hold	17	–	–	﹤0.01%	1023
2022 Q3	$2K	Buy	17 +7	+70%	+$717	﹤0.01%	1042
2022 Q2	$1K	Hold	10	–	–	﹤0.01%	1095
2022 Q1	$1K	Buy	10 +6	+150%	+$923	﹤0.01%	1098
2021 Q4	$1K	Hold	4	–	–	﹤0.01%	1187
2021 Q3	$1K	Hold	4	–	–	﹤0.01%	1108
2021 Q2	$2K	Hold	4	–	–	﹤0.01%	1079
2021 Q1	$2K	Sell	4 -1	-20%	-$460	﹤0.01%	947
2020 Q4	$2K	Hold	5	–	–	﹤0.01%	886
2020 Q3	$3K	Sell	5 -13	-72%	-$4.32K	﹤0.01%	779
2020 Q2	$2K	Sell	18 -17	-49%	-$1.49K	﹤0.01%	834
2020 Q1	$2K	Buy	+35	New	+$2.35K	﹤0.01%	832

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sandy Spring Bank's MCRB Position: Q1 2025 in Review

Sandy Spring Bank held its Seres Therapeutics (MCRB) position steady in Q1 2025 at 17 shares worth $242. The position accounts for ﹤0.01% of the portfolio, ranked #1154.

Sandy Spring Bank first reported a position in MCRB in Q1 2020 and has held it in 21 quarters since. The position peaked at $3K in Q3 2020. 63 funds tracked by Wall St. Rank hold MCRB as of Q1 2025.

Sandy Spring Bank held 17 shares of Seres Therapeutics worth $242 as of Q1 2025.
Sandy Spring Bank left its Seres Therapeutics share count unchanged in Q1 2025.
Seres Therapeutics made up ﹤0.01% of Sandy Spring Bank's portfolio in Q1 2025, its #1154 holding.
Sandy Spring Bank first reported a position in Seres Therapeutics in Q1 2020 and has held it in 21 quarters since.
Sandy Spring Bank's Seres Therapeutics position peaked at $3K in Q3 2020.
63 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2025.

Based on Sandy Spring Bank's 13F filing for Q1 2025, filed 12 May 2025.